UBS O'Connor’s AnaptysBio ANAB Stock Holding History

UBS O'Connor’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$11K	–	430
2024 Q3	$11K	Buy	+10,000	New	+$342K	﹤0.01%	460

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

UBS O'Connor's ANAB Position: Q3 2025 in Review

UBS O'Connor sold out of AnaptysBio (ANAB) in Q3 2025, closing a stake of 38,528 shares — an estimated $855K sold.

UBS O'Connor first reported a position in ANAB in Q2 2022 and held it in 11 quarters. The position peaked at $2.53M in Q2 2023. 166 funds tracked by Wall St. Rank hold ANAB as of Q3 2025.

UBS O'Connor reported no remaining AnaptysBio position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 38,528 AnaptysBio shares in Q3 2025, an estimated $855K.
UBS O'Connor first reported a position in AnaptysBio in Q2 2022 and held it in 11 quarters.
UBS O'Connor's AnaptysBio position peaked at $2.53M in Q2 2023.
166 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.